Logos Global Management’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$35.5M Buy
+250,000
New +$40.2M 1.85% 19
2025
Q3
– Sell
-150,000
Closed -$18.9M – 68
2025
Q2
$18.9M Buy
+150,000
New +$17.2M 2.09% 16
2025
Q1
– Sell
-200,000
Closed -$27.3M – 51
2024
Q4
$27.3M Buy
+200,000
New +$24.7M 3.19% 11
2023
Q4
– Sell
-150,000
Closed -$16.9M – 64
2023
Q3
$16.9M Sell
150,000
-150,000
-50% -$15.8M 2.25% 15
2023
Q2
$28.3M Buy
300,000
+100,000
+50% +$9.8M 3.85% 9
2023
Q1
$20.2M Buy
+200,000
New +$20.8M 2.9% 12
2022
Q3
– Sell
-300,000
Closed -$29.2M – 43
2022
Q2
$29.2M Sell
300,000
-175,000
-37% -$16.2M 5.37% 6
2022
Q1
$44.5M Buy
+475,000
New +$40.3M 5.77% 5

Other funds holding NBIX

Logos Global Management's NBIX Position: Q3 2026 in Review

Logos Global Management opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 250,000 shares worth $35.5M. The stake represents 1.85% of the portfolio and ranks #19 among its holdings. This is a return to the name: Logos Global Management previously reported a position in NBIX as recently as Q2 2025.

Logos Global Management first reported a position in NBIX in Q1 2022 and has held it in 8 quarters since. The position peaked at $44.5M in Q1 2022. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Logos Global Management held 250,000 shares of Neurocrine Biosciences worth $35.5M as of Q3 2026.
  • Neurocrine Biosciences was a new Logos Global Management position in Q3 2026.
  • Neurocrine Biosciences made up 1.85% of Logos Global Management's portfolio in Q3 2026, its #19 holding.
  • Logos Global Management first reported a position in Neurocrine Biosciences in Q1 2022 and has held it in 8 quarters since.
  • Logos Global Management's Neurocrine Biosciences position peaked at $44.5M in Q1 2022.
  • 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Logos Global Management's 13F filing for Q3 2026, filed 16 Nov 2026.